Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

被引：0
|
作者：
Sanborn, Rachel E.
Waqar, Saiama N.
Cho, Byoung Chul
Besse, Benjamin
Goto, Koichi
Wang, Yongsheng
Lee, Se-Hoon
Marmarelis, Melina E.
Ohe, Yuichiro
Kim, Dong-Wan
Calles, Antonio
Neal, Joel
Baik, Christina S.
Janne, Pasi A.
Curtin, Joshua C.
Patel, Bharvin
Gormley, Mike
Shreeve, S. Martin
Bauml, Joshua M.
Knoblauch, Roland E.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2166
引用
收藏
页数：3
相关论文
共 18 条
  • [1] Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
    Shu, Catherine A.
    Goto, Koichi
    Ohe, Yuichiro
    Besse, Benjamin
    Lee, Se-Hoon
    Wang, Yongsheng
    Griesinger, Frank
    Yang, James Chih-Hsin
    Felip, Enriqueta
    Sanborn, Rachel E.
    Caro, Reyes Bernabe
    Curtin, Joshua C.
    Chen, Jun
    Mahoney, Janine M.
    Trani, Leonardo
    Bauml, Joshua Michael
    Knoblauch, Roland Elmar
    Thayu, Meena
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
    Marmarelis, M. E.
    Lee, S. -H.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S.
    Li, S.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S68 - S68
  • [3] Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
    Lee, S. -H.
    Cho, B. C.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S. N.
    Shah, S.
    Trani, L.
    Chu, P. -L.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Marmarelis, M. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S147
  • [4] Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
    Shu, C. A.
    Goto, K.
    Ohe, Y.
    Besse, B.
    Park, K.
    Wang, Y.
    Griesinger, F.
    Yang, J. C-H.
    Felip, E.
    Sanborn, R. E.
    Caro, R. Bernabe
    Bauml, J. M.
    Chen, J.
    Fennema, E.
    Mahoney, J.
    Trani, L.
    Knoblauch, R. E.
    Thayu, M.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S952 - S953
  • [5] CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
    Shu, Catherine A.
    Goto, Koichi
    Cho, Byoung Chul
    Griesinger, Frank
    Yang, James Chih-Hsin
    Felip, Enriqueta
    Xie, John
    Chen, Jun
    Mahoney, Janine
    Thayu, Meena
    Knoblauch, Roland Elmar
    Trani, Leonardo
    Bauml, Joshua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
    Shih, J-Y.
    Wang, J.
    Wang, Y.
    Wang, J.
    Lee, S-H.
    Azuma, K.
    Takahashi, T.
    Tan, J-L.
    Lin, C. C.
    Ganguly, S.
    Lee, V. H. F.
    Chu, P-L.
    Shah, S.
    Diorio, B.
    Bauml, J. M.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1662
  • [7] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Moik, F.
    Riedl, J. M.
    Ay, C.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 327 - 327
  • [8] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Wang, Y.
    Lee, S. -H.
    Melosky, B.
    Shih, J. -Y.
    Wang, J.
    Azuma, K.
    Juan-Vidal, O.
    Cobo, M.
    Felip, E.
    Girard, N.
    Cortot, A. B.
    Califano, R.
    Cappuzzo, F.
    Owen, S.
    Popat, S.
    Tan, J. -l.
    Salinas, J.
    Tomasini, P.
    Gentzler, R. D.
    William, W. N.
    Reckamp, K. L.
    Takahashi, T.
    Ganguly, S.
    Kowalski, D. M.
    Bearz, A.
    MacKean, M.
    Barala, P.
    Bourla, A. B.
    Girvin, A.
    Greger, J.
    Millington, D.
    Withelder, M.
    Xie, J.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2024, 35 (01) : 77 - 90
  • [9] Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Shah, S.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 328 - 329
  • [10] Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
    Shah, Vishal
    McNatty, Andrea
    Simpson, Lacey
    Ofori, Henry
    Raheem, Farah
    BIOMEDICINES, 2023, 11 (03)
12